Investigation for T-cell mediated response to SARS-CoV-2 S peptide after SARS-CoV-2 vaccination

Investigation for T-cell mediated response to SARS-CoV-2 S peptide after SARS-CoV-2 vaccination - Investigation for T-cell mediated response to SARS-CoV-2 S peptide after SARS-CoV-2 vaccination

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046320

Enrollment

150

Registered

2021-12-13

Start date

2021-12-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Employees of Fukuoka City Hospital who have undergone interferon gamma releasing assay to assess the T-cell response to SARS-CoV-2 vaccination.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The change of interferon gamma production to SARS-CoV-2 S peptide after the third dose of COVID-19 vaccination.	—

Countries

Japan

Contacts

Public ContactNaoki Tani

Kyushu University Graduate School of Medical Sciences Medicine and Biosystemic Science

tani.kyushu.univ@gmail.com+81-92-642-5229

Outcome results